Is MDGL a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Madrigal Pharmaceuticals (MDGL) rests on Rezdiffra revenue ramp: Rezdiffra net sales grew about 127% year over year to roughly $311 million in the first quarter of 2026, crossing $1.1 billion on a trailing-twelve-month basis less than two years after launch. The bear case rests on mDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. Analysts covering it publish targets from $553.00 to $964.00 against a $544.99 price, so even the professionals disagree by 60% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Madrigal Pharmaceuticals (Nasdaq: MDGL) is a commercial-stage biopharmaceutical company built around Rezdiffra (resmetirom), an oral thyroid hormone receptor beta agonist that in March 2024 became the first FDA-approved treatment for MASH with moderate to advanced fibrosis. The company has transitioned from a clinical-stage developer into a revenue-generating commercial operation, with more than 42,250 patients on Rezdiffra as of the first quarter of 2026 and a US sales force focused on liver specialists and the roughly 460,000 diagnosed F2/F3 MASH patients being seen by those doctors. The investment picture is a concentrated bet on a single blockbuster-track drug. Rezdiffra revenue grew 127% year over year to about $311 million in the first quarter of 2026 and has surpassed $1.1 billion on a trailing basis, yet Madrigal still runs at a net loss as it invests heavily in commercial reach, label expansion and pipeline. The stock trades on the durability of that revenue ramp and on how well the company defends its first-mover position as GLP-1 drugs and FGF21 analogs move into the MASH market.
The bull case: what would have to be true for $964.00
The most optimistic published target on MDGL is $964.00, +76.9% from the $544.99 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Rezdiffra revenue ramp
Rezdiffra net sales grew about 127% year over year to roughly $311 million in the first quarter of 2026, crossing $1.1 billion on a trailing-twelve-month basis less than two years after launch. Patient count reached more than 42,250, up about 2.5x from a year earlier. The central driver is whether that adoption curve keeps compounding as more prescribers and diagnosed patients enter the funnel.
2. MASH market expansion
The diagnosed F2/F3 MASH population seen by target liver specialists in the US grew nearly 50% from about 315,000 to 460,000 patients between year-end 2023 and year-end 2025. A larger diagnosed pool and rising disease awareness expand the addressable market Rezdiffra can penetrate as the first approved therapy.
3. Label and pipeline expansion
Madrigal is pursuing broader use of resmetirom, including in earlier and more advanced (compensated cirrhosis) MASH populations, and has added assets through business development, including an RNAi MASH deal sourced from China. Success in widening the label and building a multi-asset pipeline would reduce reliance on a single indication.
4. Path toward profitability
The company reported a net loss of about $94 million in the first quarter of 2026 against roughly $404 million of operating expenses, ending the period with about $818 million in cash and marketable securities. The bull case rests on revenue scaling past a heavy commercial and R&D cost base to reach sustained profitability.
The bear case: what would have to be true for $553.00
The most pessimistic published target is $553.00, +1.5% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Madrigal Pharmaceuticals is worth if the risks below bite instead of the drivers above.
MDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. Competition is intensifying: Novo Nordisk's Wegovy won FDA approval in MASH in 2025, and late-stage rivals include Viking Therapeutics' VK2809 and FGF21 analogs such as Akero's efruxifermin, 89Bio's pegozafermin and GSK's efimosfermin. The company remains unprofitable and could need additional capital or carry debt (it has an outstanding term loan) if losses persist. Valuation is rich relative to current sales, leaving little room for execution stumbles. Biotech-specific risks around clinical trials, regulatory decisions and manufacturing also apply.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MDGL already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MDGL
15 analysts cover MDGL, with an average target of $680.00 (+24.8% against $544.99) and a split of 15 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the MDGL forecast and price target page.
How is MDGL valued? (as of JULY 2026)
Snapshot for MDGL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.1B
- Q1 2026 Rezdiffra net sales: ~$311M (+127% YoY)
- Q1 2026 net loss: ~$94M
- Market cap: ~$12B
- Price/sales (TTM): ~11x
- Cash and marketable securities: ~$818M
Madrigal is valued as a high-growth commercial biotech, trading around 11 times trailing sales while still reporting quarterly losses as it funds commercialization. The market is pricing in continued rapid revenue growth from Rezdiffra rather than current earnings. Figures are approximate and drawn from first-quarter 2026 reporting.
How do you decide if MDGL is a buy?
Rather than asking whether MDGL is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MDGL indirectly through an index or sector ETF before adding more.
What would change your mind on MDGL
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Rezdiffra revenue ramp stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: mDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MDGL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MDGL against your real portfolio and see your actual exposure before deciding.
Investing in Madrigal Pharmaceuticals with AI
Connect the broker you already use and ask Walnut's AI how MDGL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is MDGL a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Rezdiffra revenue ramp, with revenue (ttm) at ~$1.1B. The bear case rests on mDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. Analysts covering it are spread from $553.00 to $964.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MDGL?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. MDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $553.00, +1.5% from the $544.99 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for MDGL?
+
Rezdiffra revenue ramp. Rezdiffra net sales grew about 127% year over year to roughly $311 million in the first quarter of 2026, crossing $1.1 billion on a trailing-twelve-month basis less than two years after launch. The most optimistic analyst target on MDGL is $964.00, +76.9% from the $544.99 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for MDGL?
+
MDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. Competition is intensifying: Novo Nordisk's Wegovy won FDA approval in MASH in 2025, and late-stage rivals include Viking Therapeutics' VK2809 and FGF21 analogs such as Akero's efruxifermin, 89Bio's pegozafermin and GSK's efimosfermin. The company remains unprofitable and could need additional capital or carry debt (it has an outstanding term loan) if losses persist. Valuation is rich relative to current sales, leaving little room for execution stumbles. Biotech-specific risks around clinical trials, regulatory decisions and manufacturing also apply. The most pessimistic published target is $553.00, +1.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Madrigal Pharmaceuticals do?
+
Madrigal Pharmaceuticals (Nasdaq: MDGL) is a commercial-stage biopharmaceutical company built around Rezdiffra (resmetirom), an oral thyroid hormone receptor beta agonist that in M
What would have to change for MDGL to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Rezdiffra revenue ramp) stalling in the reported numbers rather than in the narrative, the risk above (mDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Madrigal Pharmaceuticals do?
+
Madrigal is a commercial-stage biopharmaceutical company focused on liver and metabolic disease. Its lead product, Rezdiffra (resmetirom), is the first FDA-approved treatment for MASH with moderate to advanced fibrosis and drives essentially all of the company's revenue.
What exchange is MDGL listed on?
+
MDGL trades on the Nasdaq Stock Market under the ticker MDGL. It is a US-based company, so investors can access it through a standard US brokerage account.
What is Rezdiffra?
+
Rezdiffra (resmetirom) is an oral, once-daily thyroid hormone receptor beta agonist. Approved by the FDA in March 2024, it was the first therapy cleared specifically for MASH (formerly called NASH) in adults with moderate to advanced liver fibrosis.
Walnut is informational, not investment advice, and gives no verdict on MDGL. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.